PMC:7195088 / 27345-27732 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T135","span":{"begin":62,"end":70},"obj":"Disease"},{"id":"T136","span":{"begin":218,"end":226},"obj":"Disease"},{"id":"T137","span":{"begin":267,"end":275},"obj":"Disease"}],"attributes":[{"id":"A135","pred":"mondo_id","subj":"T135","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A136","pred":"mondo_id","subj":"T136","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A137","pred":"mondo_id","subj":"T137","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Comparison of hydroxychloroquine vs. placebo in patients with COVID-19 and under biological treatment and/or JAK inhibitors. Double-blind RCT (NCT04330495, not yet recruiting). Primary endpoints: (a) incidence rate of COVID-19 (follow-up 27 weeks); (b) prevalence of COVID-19 (follow-up 27 weeks); (c) case fatality rate (follow-up 27 weeks); (d) ICU admission rate (follow-up 27 weeks)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T145","span":{"begin":197,"end":198},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T146","span":{"begin":238,"end":240},"obj":"http://purl.obolibrary.org/obo/CLO_0050509"},{"id":"T147","span":{"begin":250,"end":251},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"},{"id":"T148","span":{"begin":287,"end":289},"obj":"http://purl.obolibrary.org/obo/CLO_0050509"},{"id":"T149","span":{"begin":332,"end":334},"obj":"http://purl.obolibrary.org/obo/CLO_0050509"},{"id":"T150","span":{"begin":377,"end":379},"obj":"http://purl.obolibrary.org/obo/CLO_0050509"}],"text":"Comparison of hydroxychloroquine vs. placebo in patients with COVID-19 and under biological treatment and/or JAK inhibitors. Double-blind RCT (NCT04330495, not yet recruiting). Primary endpoints: (a) incidence rate of COVID-19 (follow-up 27 weeks); (b) prevalence of COVID-19 (follow-up 27 weeks); (c) case fatality rate (follow-up 27 weeks); (d) ICU admission rate (follow-up 27 weeks)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T366","span":{"begin":14,"end":32},"obj":"Chemical"},{"id":"T367","span":{"begin":113,"end":123},"obj":"Chemical"}],"attributes":[{"id":"A366","pred":"chebi_id","subj":"T366","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A367","pred":"chebi_id","subj":"T367","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"}],"text":"Comparison of hydroxychloroquine vs. placebo in patients with COVID-19 and under biological treatment and/or JAK inhibitors. Double-blind RCT (NCT04330495, not yet recruiting). Primary endpoints: (a) incidence rate of COVID-19 (follow-up 27 weeks); (b) prevalence of COVID-19 (follow-up 27 weeks); (c) case fatality rate (follow-up 27 weeks); (d) ICU admission rate (follow-up 27 weeks)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T205","span":{"begin":125,"end":176},"obj":"Sentence"},{"id":"T206","span":{"begin":177,"end":387},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Comparison of hydroxychloroquine vs. placebo in patients with COVID-19 and under biological treatment and/or JAK inhibitors. Double-blind RCT (NCT04330495, not yet recruiting). Primary endpoints: (a) incidence rate of COVID-19 (follow-up 27 weeks); (b) prevalence of COVID-19 (follow-up 27 weeks); (c) case fatality rate (follow-up 27 weeks); (d) ICU admission rate (follow-up 27 weeks)."}